NYSE:GSK
GlaxoSmithKline PLC (GSK)
Financials 
Technical Analysis 
Jun 4, 2026, 12:00 amThis summary was created by AI, based on 5 opinions in the last 12 months.
GlaxoSmithKline PLC (GSK) has received positive reviews from various experts, indicating that the stock is progressing well. Each analysis suggests a series of trailing stop recommendations, with significant gains reported for previous top picks, ranging from 17.2% to 80%. Despite challenges in the vaccine sector, where sentiment is currently low, GSK's future prospects seem promising, particularly with ongoing trials that may enhance its drug portfolio. The consensus among experts reflects a cautious but optimistic view, highlighting the importance of disciplined trading strategies to safeguard gains. Overall, while some areas present challenges, the company's trajectory is largely viewed favorably.
;fill-opacity:1;'/%3e%3cpath%20d='M31%2018.6001V30H8V18.6001L14.1334%2022.4334L19.4999%2014L24.8669%2022.4334L31%2018.6001Z'%20fill='%23EE5432'%20style='fill:%23EE5432;fill:color(display-p3%200.9340%200.3310%200.1956);fill-opacity:1;'/%3e%3c/svg%3e){kind=small}
Premium contentPremium content
Premium contentPremium contentPremium contentPremium contentWe reiterate GSK as a TOP PICK. We like that cash reserves are holding steady, despite an aggressive retirement of debt. It trades at 22x earnings and supports a 18% ROE. The solid dividend is backed by a payout ratio under 50% of cash flow. The company is partnering with another pharma to develop Parkinson's disease treatments. We continue to recommend a stop at $27, looking to achieve $41 -- upside potential over 20%. Yield 4.6%
(Analysts’ price target is $40.89)Premium contentThis large global biopharma company has reported continued success in a oncology based treatment for a blood cancer effecting 180,000 new patients annually. The company is building cash reserves while debt is retired. It trades at 22x earnings and supports a 21% ROE. We recommend setting a stop-loss at $27, looking to achieve $45 -- upside potential of 26%. Yield 4.5%
(Analysts’ price target is $45.07)
They sold their personal care business to generate a lot of capital. They're strong in vaccines, but don't have a strong pipeline of drugs. So, they need to buy other companies to make up for that. Not a high PE and pays a good dividend. The key is what they will do with their capital.
Great dividend yield of 6.3%, trades at only 10x earnings. Cheap, you can own it here. Grew vaccine business. New CEO shed some divisions, so now more of a pure pharma company, which has risks. Have to worry about pipeline constantly. JNJ, for example, is more diversified, and that's what he prefers.
'%20fill='%23ffffff'%3e%3cg%20id='Pager'%20transform='translate(423.000000,%201755.000000)'%3e%3cpath%20d='M243.295367,17.286474%20C243.68919,16.9045087%20244.327703,16.9045087%20244.721525,17.286474%20L249,21.4361302%20L253.278475,17.286474%20C253.672297,16.9045087%20254.31081,16.9045087%20254.704633,17.286474%20C255.098456,17.6684393%20255.098456,18.2877274%20254.704633,18.6696927%20L249.35654,23.856763%20C249.159628,24.0477457%20248.840372,24.0477457%20248.64346,23.856763%20L243.295367,18.6696927%20C242.901544,18.2877274%20242.901544,17.6684393%20243.295367,17.286474%20Z'%20id='Path'%20transform='translate(249.000000,%2020.500000)%20rotate(-90.000000)%20translate(-249.000000,%20-20.500000)%20'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
GlaxoSmithKline PLC (GSK) Frequently Asked Questions
What is GlaxoSmithKline PLC stock symbol?
GlaxoSmithKline PLC is a American stock, trading under the symbol GSK (previously GSK-N on Stockchase) on the New York Stock Exchange (GSK). It is usually referred to as NYSE:GSK or GSK
Is GlaxoSmithKline PLC a buy or a sell?
In the last year, 6 stock analysts published opinions about GSK (previously GSK-N on Stockchase). 5 analysts recommended to BUY the stock. 1 analyst recommended to SELL the stock. The latest stock analyst recommendation is RISKY. Read the latest stock experts' ratings for GlaxoSmithKline PLC.
Is GlaxoSmithKline PLC a good investment or a top pick?
GlaxoSmithKline PLC was recommended as a Top Pick by Paul Harris, CFA on 2023-04-05. Read the latest stock experts ratings for GlaxoSmithKline PLC.
Why is GlaxoSmithKline PLC stock dropping?
Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for help on deciding if you should buy, sell or hold the stock.
Is GlaxoSmithKline PLC worth watching?
6 stock analysts on Stockchase covered GlaxoSmithKline PLC in the last year. It is a trending stock that is worth watching.
What is GlaxoSmithKline PLC stock price?
On 2026-06-04, GlaxoSmithKline PLC (GSK) stock closed at a price of $51.27.
Our PAST TOP PICK with GSK is progressing well. To remain disciplined, we recommend trailing up the stop (from $45) to $50 at this time.